Biomednewsbreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Berubicin's Potential In Glioblastoma Treatment During KOL Connect Event
CNS Pharmaceuticals (NASDAQ: CNSP) , focused on innovative cancer therapies for brain and central nervous system cancers, recently participated in ...
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights Berubicin’s Potential During KOL Connect Event
Detailed price information for Cns Pharmaceuticals Inc (CNSP-Q) from The Globe and Mail including charting and trades.
CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment
Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael Weller Access the segment ...
Biomednewsbreaks CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Granted Nasdaq Extension For Compliance
CNS Pharmaceuticals (NASDAQ: CNSP) announced that it received an exception from the nasdaq Hearings Panel, granting the company until March 11, 2025, to meet the minimum bid price requirement under ...
CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
HOUSTON, TX / ACCESSWIRE / November 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a ...
CNS Pharmaceuticals (NASDAQ: CNSP) Secures $3 Million in Registered Direct Offering
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing treatments for cancers affecting the brain and central nervous system, has announced that it has entered into ...
bovnews12d
CNS Pharmaceuticals (CNSP): Climbing Out of the Depths—What’s Next?
As CNS Pharmaceuticals moves forward with its offerings and the continued development of Berubicin, the path ahead will be pivotal. Investors and stakeholders will be watching closely to see how the ...
Science Daily14d
Dinosaurs News
July 24, 2024 — Scientists have discovered that the serrated edges of Komodo dragons' teeth are tipped with iron. The study gives new insight into how Komodo dragons keep their teeth razor-sharp ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Finanznachrichten26d
CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment
The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the ...
Nasdaq26d
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment
The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the ...
Morningstar26d
CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...